Clinical Trial Update: A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) [Phase 3]

View source ↗

Summary

A Phase 3 multicenter trial evaluating the PROMUS Element everolimus-eluting coronary stent system has completed, with the results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Coronary Artery Disease

Drugs mentioned

• PROMUS Element Everolimus-Eluting Coronary Stent System (everolimus-eluting coronary stent system)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Atherosclerosis, Coronary Artery Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-03-07